Skip to main content
University of Michigan Innovation Partnerships
University of Michigan Innovation Partnerships

Portfolio

MedHub, Inc.

Tracking and scheduling program for medical residents
(2003)

Soar Technology

Intelligent systems for defense, government, and commercial applications that emulate human decision making
(2003)

Eprogen, Inc.

Proteomics utilizing liquid-based protein separations
(2002)

Velcura Therapeutics, Inc.

Developing novel therapies for osteoporosis and other bone diseases
(2002)

BlueWillow Biologics

Non-toxic solvent-detergent lipid suspensions with antimicrobial properties [formerly NanoBio Corporation]
(2001)

KeraCure, Inc.

Interactive cell-based dressing for the treatment of chronic wounds
(2001)

Molecular Imaging Research Preclinical Services

Imaging intracellular events (Formerly Molecular Therapeutics)
(2001)

OncoMed Pharmaceuticals, Inc.

Biological therapeutics targeting cancer stem cells
(2001)

Originus, Inc.

Discovering molecular origins of complex disorders using integrated array techniques
(2001)

Translume, Inc.

Advanced glass micromachining providing new ways to advance sensing, microfluidic and optical communication capabilities
(2001)

Xeotron Corp

Microarray nucleic acid processing chip
(2001)

HandyLab, Inc.

Developing novel clinical diagnostic testing products to improve infectious disease testing
(2000)

Rubicon Genomics

Amplification technologies for molecular diagnostics and research
(2000)

HealthMedia, Inc.

Delivers tailored behavioral support programs to health management organizations and pharmaceutical companies
(1998)

IntraLase

Medical device company that developed an automated procedure for laser vision correction, procedure known as "IntraLasik" or "Bladeless Lasik"
(1998)

CardioGene Therapeutics

CardioGene is focused on the development of novel gene therapy products for the treatment of cardiovascular disease (Formerly Genocor, Inc.)
(1997)

Biotherapies, Inc.

Commercializing Mammastatin Serum Assay technology used to screen breast cancer risk
(1996)

IDUN Pharmaceuticals, Inc.

Therapeutic applications focused on inhibiting caspase activity as treatments for liver disease and inflammation
(1994)
1 7 8 9 10 11